Zebrafish models in neuropsychopharmacology and CNS drug discovery

Kanza M. Khan, Adam D. Collier, Darya A. Meshalkina, Elana V. Kysil, Sergey L. Khatsko, Tatyana Kolesnikova, Yury Yu Morzherin, Jason E. Warnick, Allan V. Kalueff*, David J. Echevarria

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

143 Citations (Scopus)

Abstract

Despite the high prevalence of neuropsychiatric disorders, their aetiology and molecular mechanisms remain poorly understood. The zebrafish (Danio rerio) is increasingly utilized as a powerful animal model in neuropharmacology research and in vivo drug screening. Collectively, this makes zebrafish a useful tool for drug discovery and the identification of disordered molecular pathways. Here, we discuss zebrafish models of selected human neuropsychiatric disorders and drug-induced phenotypes. As well as covering a broad range of brain disorders (from anxiety and psychoses to neurodegeneration), we also summarize recent developments in zebrafish genetics and small molecule screening, which markedly enhance the disease modelling and the discovery of novel drug targets.

Original languageEnglish
Pages (from-to)1925-1944
Number of pages20
JournalBritish Journal of Pharmacology
Volume174
Issue number13
DOIs
Publication statusPublished - 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Zebrafish models in neuropsychopharmacology and CNS drug discovery'. Together they form a unique fingerprint.

Cite this